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Enhanced nanoparticle delivery exploiting 
tumour‑responsive formulations
Lindsey A. Bennie, Helen O. McCarthy and Jonathan A. Coulter*
Nanoparticles in the clinic
In the last 20 years, nanoparticle delivery systems have been at the forefront of research 
for improving cancer therapeutic delivery and efficacy. A number of nano-therapies 
have been FDA approved for the treatment of cancer such as Doxil® and Vyxeros®, 
with approved therapies most often being liposomal in nature, delivering pre-approved 
chemotherapeutics. However, despite the wealth of promising pre-clinical data for the 
use of nanoparticle therapeutics, successful clinical translation has proved challenging. 
One example of this is Aroplatin™ a platinum analogue (cis–trans-R,R-1,2- diaminocy-
clohexane decanoate platinum (II) encapsulated within a liposome. In  vivo, Aroplatin 
was shown to successfully increase survival of mice bearing L1210 leukemia following 
both intravenous and intraperitoneal administration, compared to cisplatin delivered as 
a free drug. Aroplatin also increased the survival time of mice bearing reticulosarcoma 
liver metastasis by 37% over free drug (Perez-Soler et al. 1987). However, in the clinical 
setting benefits of Aroplatin were modest with only 5.6% of patients displaying a partial 
Abstract 
Nanoparticles can be used as drug carriers, contrast agents and radiosensitisers for the 
treatment of cancer. Nanoparticles can either passively accumulate within tumour sites, 
or be conjugated with targeting ligands to actively enable tumour deposition. With 
respect to passive accumulation, particles < 150 nm accumulate with higher efficiency 
within the tumour microenvironment, a consequence of the enhanced permeability 
and retention effect. Despite these favourable properties, clinical translation of nano-
therapeutics is inhibited due to poor in vivo stability, biodistribution and target cell 
internalisation. Nano-therapeutics can be modified to exploit features of the tumour 
microenvironment such as elevated hypoxia, increased pH and a compromised extra-
cellular matrix. This is in contrast to cytotoxic chemotherapies which generally do not 
exploit the characteristic pathological features of the tumour microenvironment, and 
as such are prone to debilitating systemic toxicities. This review examines strategies for 
tumour microenvironment targeting to improve nanoparticle delivery, with particular 
focus on the delivery of nucleic acids and gold nanoparticles. Evidence for key research 
areas and future technologies are presented and critically evaluated. Among the most 
promising technologies are the development of next-generation cell penetrating pep-
tides and the incorporation of micro-environment responsive stealth molecules.
Keywords: Tumour microenvironment, Nano-therapeutics, Gold nanoparticles, Cell-
penetrating peptide, Cleavable stealth molecules, Nucleic acids
Open Access
© The Author(s) 2018. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creat iveco mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and 
indicate if changes were made.
REVIEW
Bennie et al. Cancer Nano            (2018) 9:10  
https://doi.org/10.1186/s12645‑018‑0044‑6 Cancer Nanotechnology
*Correspondence:   
j.coutler@qub.ac.uk 
School of Pharmacy, Queens 
University Belfast, Lisburn 
Road, Belfast BT9 7BL, UK
Page 2 of 20Bennie et al. Cancer Nano            (2018) 9:10 
response (Liu et al. 2013). Additionally, concerns with regards to nanoparticle stability 
and potential toxicity arose due to large lipid loading and critical organ accumulation. 
More recently, Livatag® doxorubicin nanoparticles used in the treatment of hepatocel-
lular carcinoma exhibited superiority in pre-clinical studies but failed to deliver patient 
benefit in phase III studies over standard therapeutics such sorafenib, gemcitabine and 
oxaliplatin. As such Livatag® clinical trials were halted.
A number of common factors inhibit the transition of nanoparticle therapeutics from 
the bench to the bedside. These include formulation complexity, pharmaceutical stability 
(biocompatibility and degradability), poor methodology of pre-clinical studies (e.g. ran-
domisation), upscaling and a lack of standardisation with regards pre-clinical validation 
(Hua et al. 2018). Another major contributing factor is an over-reliance on passive target-
ing, exploiting the widely cited enhanced permeability retention effect (EPR). Typically 
this approach results in < 1% of the systemic administered dose reaching the target desti-
nation (Wilhelm et al. 2016). Importantly, insufficient tumour specificity leads to greater 
systemic toxicity, poor disease control and premature termination of clinical trials. An 
example of this occurred using an albumin-bound paclitaxel nanoparticle for the treat-
ment of refractory multiple myeloma. Withdrawn in November 2014 (NCT01646762), 
the trial studied the therapeutic efficacy of nab-paclitaxel nanoparticles on 13 patients 
who had all previously failed with several rounds of different chemotherapies. Of the 
13 patients enrolled 2 patients presented with partial disease response, with 6 patients 
displaying signs of disease progression. Given the advanced state of disease progression 
of these patients a reasonable 3.7 month increase in survival was shown. However, the 
trial was severely limited by a series of adverse side effects, ultimately leading to termi-
nation of the study. This was demonstrated in the fact that 85% of patients experienced 
peripheral sensory neuropathy, with > 50% of patients developing severe nausea. In one 
instance a patient developed grade 5 sepsis, influenced by drug-induced neutropenia 
which ultimately proved fatal. However, since the withdrawal of this trial, the use of nab-
paclitaxel has been explored and NICE approved for the treatment of pancreatic cancer, 
where long-term prognosis is particularly poor. These and other similar example serve 
to highlight the importance of incorporating tumour-responsive elements into nanopar-
ticle design to help limit systemic toxicities while simultaneously enhancing therapeutic 
efficacy.
The tumour microenvironment
Cancers arise from genetic mutations, typically characterised by uncontrollable cell pro-
liferation that results in the formation of a neoplastic mass, that can lead to secondary 
metastatic lesions (Hanahan and Weinberg 2011). As such, most early cytotoxic chemo-
therapeutic agents were designed to preferentially destroy cells undergoing continuous 
proliferation. However, standard chemotherapeutics such as docetaxel, doxorubicin and 
gemcitabine often result in minimal therapeutic differentials, causing widespread toxic-
ity, with modest benefits in terms of overall survival (Pan et  al. 2014; Huanwen et  al. 
2009). Therefore, it is contingent upon scientists to exploit the ever-increasing knowl-
edge of the unique tumour microenvironment (TME), to designing the next generation 
of targeted therapeutics.
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The TME is a dynamic network of immune, stromal, tumour and endothelial cells, 
the latter of which form a dysfunctional vasculature producing elevated secretion of 
inflammatory and growth signalling molecules (Fig.  1, Table  1). The complex signal-
ling interplay within the TME contributes to neoplastic survival and growth by sup-
plying nutrients,  O2 and stimulatory factors. In contrast to healthy tissue, the TME is 
characterised by a high interstitial fluid pressure (IFP) and a low intracellular pH (pH 
between 6.0 and 7.0), both of which impede the delivery and efficacy of current thera-
peutics (Kato et al. 2013). Additionally, the complexity of the tumour microenvironment 
(TME) has been shown to result in premature degradation of cargo, reduction in circula-
tion times and poor target cell uptake. Despite this, the physiological differences of the 
TME can be exploited using nanotechnology to ensure targeted delivery of therapeutic 
cargoes. Within this review, the latest developments in nano-therapeutics are discussed 
along with potential pitfalls and areas for future development.
TME and vasculature
Nanoparticle therapy and high IFP
Metallic and non-metallic nanoparticles hold significant potential for use in diagnostic 
imaging, as radiosensitisers and as a means of repurposing existing therapeutics (Botch-
way et al. 2015; Brown et al. 2010). Nanoparticles preferentially accumulate in tumour 
tissue over healthy tissue due to the enhanced permeability and retention (EPR) effect 
(Kobayashi et  al. 2014; Nakamura et  al. 2016; Ngoune et  al. 2016). Growing tumours 
require vasculature, however, the tumour vascular network fails to undergo sufficient 
vascular remodelling, as a result dysfunctional vasculature with poor lymphatic drainage 
forms. Impaired lymphatic drainage results in an imbalance of molecular fluid pressure 
creating high interstitial fluid pressure (IFP) ranging from 40 to 60 mmHg, compared to 
between 3 and 10 mmHg in healthy tissue (Omidi and Barar 2014).
Interstitial fluid pressure regulates transcapillary flow, therefore, influencing the 
uptake of high molecular weight compounds such as chemotherapeutics that are trans-
ported via convection (Heldin et al. 2004). Salnikov et al. (2003) reported that high IFP 
Fig. 1 Schematic representation of the cells and vasculature of the tumour microenvironment. There are 
several targets within the TME that distinguish tumour tissue from healthy tissue. These include: cell profile, 
vasculature, altered oxygenation status and
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Table 1 Cellular involvement in the tumour microenvironment
Cell type Role References
T-lymphocytes CD8+: cytotoxic, good for prognosis
CD4+: Th1—production of IL-2 
and IFN-γ. Important for immune 
defense
CD4+: Th2—tumour promot-
ing, linked with inflammatory 
phenotype. Secrete inflammatory 
cytokines. Poor prognosis if in 
high number
Botchway et al. (2015), Brown et al. 
(2010), Burroughs et al. (2013)
T-Regulatory (T-Reg)
(lymphocyte)
Tumour promoting/ suppress 
tumour immunity
Produce IL-10 and TGF-β allowing 
for enhanced cell growth
Reduce cellular response to oxida-
tive stress thereby contributing to 
the development of therapeutic 
resistance
Cathcart et al. (2015), Cheng et al. 
(2017), Coulter et al. (2013)
Pericytes Contractile cells
Differentiate to stromal fibroblasts 
contributing to invasion/metas-
tasis
Provide structural support for blood 
vessels
Decreased expression in TME allow-
ing for increased metastasis
Cox et al. (2014), Dai et al. (2011)
B-lymphocytes Located in the invasive margin of 
the tumour and lymph nodes
Involved in antitumour humoral 
immunity
Release of cytokines and lympho-
toxin activating pro-inflammatory 
pathways such as NF-κB
Deshayes et al. (2005), Dixit et al. 
(2015), Erler et al. (2006)
Natural Killer (NK) Innate cytotoxic lymphocytes
Normally powerful cytotoxic activity 
but decreased presence in TME
Influences a tumours ability to 
control tumour growth
Important role in response to some 
targeted antibody therapies such 
as trastuzumab
Fais et al. (2014), Feuerecker et al. 
(2015)
Adipocytes Aid recruitment of malignant cells 
due to presence of free fatty acids
Act as “fuel” for cancer cells
Assist in recruitment of mac-
rophages, polarizing to M2 
phenotype
Produce IL-6, CCL2 and TNF-α
Gao et al. (2017), Gialeli et al. (2011), 
Haley and Frenkel (2008)
Dendritic Normal immune function—antigen 
presenting and processing cells
Reduction in antigen presenting 
function
Accumulation within tumour 
associated with increased patient 
survival
Hamdan and Zihlif (2014), Hanahan 
and Weinberg (2011)
Tumour associated neutrophils 
(TAN)
Promote primary tumour growth
Enhance angiogenesis
Facilitate ECM degradation
ROS and RNS production—DNA 
damage
Hatakeyama et al. (2007), Heitz et al. 
(2009), Heldin et al. (2004), Hill 
et al. (2008)
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impedes transcapillary transport, uptake and therapeutic efficacy of traditional cytotoxic 
chemotherapeutics such as 5-Fluorouracil (5-FU). Using a Wistar-Moller rat mammary 
carcinoma model, the authors demonstrated that reversal of high IFP using s.c. injection 
of Prostaglandin E1  (PGE1) resulted in a 40% increase in 5-FU uptake compared to rats 
receiving no pre-treatment. Despite this the effect was transient, remaining for a maxi-
mum of 1 h post  PGE1 administration. This suggests that repeated dosing of  PGE1 would 
be necessary to maintain enhanced 5-FU uptake and efficacy, highlighting practical limi-
tations to this approach (Salnikov et al. 2003).
An alternative to this strategy is to develop hybrid nanoparticle drug conjugates. Nan-
oparticles are attractive due to their versatility as can be modified in terms of both size, 
surface charge and functionalisation to take advantage of the TME and high IFP ena-
bling greater target site drug accumulation.
Gao et al. (2017) examined how nanoparticles can be used not only to enhance chemo-
therapy delivery through the EPR effect but by also reducing tumour IFP. In this instance 
the authors synthesised a complex tumour-responsive gelatin-coated lipid nanoparticle 
(GNP) designed to reduce tumour IFP while simultaneously enhancing the tumour spe-
cific release of the chemotherapeutics docetaxel and quercetin. These two chemothera-
peutics were encapsulated within a lipid core composed of glycerine monosterate, egg 
phosphatidyl choline and capric triglyceride. The lipid core is encapsulated with an outer 
gelatin layer which contains the tyrosine kinase inhibitor imantinib. Imantinib was used 
to reduce tumour IFP by inhibiting the expression if Bcr-Abl and platelet derived growth 
factor (PDGF), blocking interactions between the extracellular matrix and cancer-asso-
ciated fibroblasts, thus reducing IFP. The outer particle layer was composed of gelatin, 
Table 1 (continued)
Cell type Role References
Tumour associated macrophages 
(TAM)
Highly expressed in hypoxic, 
necrotic areas
Associated with poor prognosis
Involved in cell migration, invasion 
and metastasis and epithelial-
mesenchymal transition
Increase expression of MMP
Hua et al. (2018), Huanwen et al. 
(2009), Kanapathipillai et al. (2012)
Myeloid derived suppressor 
cell(MDSC )
Inhibitory immune cell
Promote tumour growth
Inhibit  CD8+ T cell activity by 
increasing NOS2 expression
Hamdan and Zihlif (2014), Kato et al. 
(2013), Kobayashi et al. (2014)
Vascular endothelial Line the lumen of blood vessels 
essential for nutrient/oxygen 
supply
In TME—abnormal in shape, chaotic 
branching promoting a leaky 
vasculature
Stimulate inflammation and 
metastasis
Kumar et al. (2013), Li et al. (2013)
Cancer associated fibroblasts (CAF) Involved in organ fibrosis and can-
cer development
Secrete chemo-attractants and 
growth factors—e.g. CXCL12 
promotes growth and survival of 
malignant cells
Enhances MMP production and 
neovascularization
Li et al. (2004, 2016), Liu et al. (2013)
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enabling tumour responsiveness, the gelatin layer is degraded by matrix metallopro-
teinases (MMP), overexpressed within the TME. Importantly, this approach improves 
drug-specific release within the TME, avoiding off-target toxicity. MTT viability assays 
demonstrated that the nanoparticle system significantly reduced the  IC50 concentration 
for the combination of docetaxel and quercetin (6.18 ± 0.35 μg/ml) compared to that 
of free drug alone (13.43 ± 0.8 μg/ml). The authors attribute this increased efficacy to 
enhanced target cell internalisation, however, uptake studies show less endocytosis of the 
gelatin-coated nanoparticle compared to the lipid only particle. It is, therefore, likely that 
the increased toxicity is due to the inclusion of imantinib. Imantinib reduced tumoural 
IFP by > 40% (17.2 mmHg) in a nude 4T1 xenograft mouse model, with control animals 
exhibiting an IFP of 29.18 mmHg. Importantly, the impact of both in vitro enhanced tox-
icity and in vivo reduced IFP translated to a significant anti-tumour effect with a 2.8 fold 
increase in tumour growth delay and a 72.5% reduction in the formation of pulmonary 
metastases for GPN treated animals (Docetaxel, Imantinb 10 mg kg, quercetin 5 mg kg) 
(Gao et  al. 2017). This study outlines a potentially promising tumour-specific delivery 
vehicle for chemotherapeutics that have previously been shown to induce off-target tox-
icity. The inclusion of gelatin and imantinib theoretically enable tumour specificity, how-
ever, limited information with respect to in vivo biodistribution, particularly within the 
liver and spleen, leave unanswered questions with respect to targeting efficacy, and the 
full clinical potential.
Tumour vasculature and hypoxia
Accelerated proliferation coupled with a deficient vasculature often results in dynamic 
tumour hypoxia. Tumours adapt to chronic hypoxia inducing changes in gene expression 
through the activation of pro-survival and metastatic genes such as nuclear factor kappa 
beta (NF-κB), Hypoxia-inducible factor-1-alpha (HIF-1-α), PIM-1 oncogene (PIM-1) 
and endothelin-1 (EDN 1) (Hamdan and Zihlif 2014; Dai et al. 2011). In turn, hypoxia 
has been directly correlated to an aggressive, metastatic tumour phenotype with hypoxic 
tumours generally exhibiting resistance to conventional cancer treatments (Rockwell 
et al. 2009). Tumour hypoxia has been harnessed in several different ways for the treat-
ment of cancer, including the development of nano-formulations to enhance the delivery 
of encapsulated chemotherapies. Thambi et al. (2014) assessed the use of self-assembled 
hypoxia smart nitroimidazole-dextran nanoparticles to enhance the delivery and ther-
apeutic effect of the chemotherapeutic doxorubicin (DPX-HR-NP). Under low oxygen 
tensions, the nitro group of nitroimidazole is converted to an amino group, altering 
the hydrophilicity of the nanoparticle complex. The authors report that this conversion 
allows for a water-soluble particle, enabling an enhanced release of hydrophobic drugs 
in hypoxic conditions. The authors demonstrated a 40% increase in doxorubicin release 
under hypoxic conditions compared to normoxia when encapsulated in the nitroimida-
zole-dextran nanoparticle. This corresponded to an increased tumour-specific in  vivo 
accumulation of DPX-HR-NP, four-fold greater than measured in any normal organ. 
Unsurprisingly, DPX-HR-NP also significantly reduced tumour volume of SCC7 bearing 
nude mice when delivered intravenously, compared to that of mice treated with an equal 
concentration (5 mg/kg) of free doxorubicin, observing time-matched tumour volumes 
of 700 mm3 and 300 mm3, respectively (Thambi et al. 2014).
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The hypoxic properties of the TME can be directly targeted using siRNA therapeutics. 
Hypoxia-inducible factor-1-alpha (HIF-1-α) is overexpressed under hypoxic conditions, 
driving a corresponding increase in the expression of downstream targets such as vascu-
lar endothelial growth factor (VEGF), involved in angiogenesis, glucose metabolism and 
invasion (Burroughs et al. 2013). Successful inhibition of HIF-1 has been demonstrated 
in both prostate and lung cancer using chemical inhibitors such as PX-478 and topote-
can. However, clinical effectiveness is greatly reduced by serious adverse effects includ-
ing neutropenia and acute weight loss, as such alternative strategies have been pursued 
(Welsh et al. 2004). Liu et al. (2012) investigated the use of siRNA targeted to HIF-1-α 
to suppress expression and inhibit the growth of hypoxic prostate tumours (Liu et  al. 
2012). HIF-1-α siRNA was delivered through self-assembled micelle nanoparticles com-
posed of two polymers, poly-ε-caprolactone and poly-2-aminoethylethyenephosphate. 
Nanoparticles were 58 ± 3.4  nm in diameter with a surface charge of 24.3 ± 2.31  mV. 
Maximal inhibition of HIF-1 expression was demonstrated using 400  nM of HIF-1-α 
siRNA, resulting in reduced tubule formation and enhanced wound closure compared to 
untreated, hypoxic PC-3 cells. Furthermore, suppression of HIF-1 inhibited PC-3 xeno-
graft growth in athymic mice following i.v. injection with 2 mg of siRNA loaded nano-
particles every second day over 22 days. At the experimental endpoint, siRNA treated 
tumour volume was measured as 280 mm3 compared to 500 mm3 for mice treated with 
blank nanoparticles (Liu et al. 2012). This study highlights the potential therapeutic ben-
efit of HIF-1 inhibition in hypoxic tumours. However, HIF-1 inhibition may not be a 
viable therapeutic approach for all patient cohorts. Zhang et al. (2010) have shown that 
inhibition of HIF-1 negatively impacts the normal angiogenic response with HIF-1 
heterozygous null mice exhibiting delayed wound healing, a side effect that would be 
particularly problematic in elderly or diabetic patient cohorts (Zhang et al. 2010). How-
ever, as the effects of siRNA therapeutics are short-lived and transient, hypoxia-induced 
treatment resistance could be overcome, enabling the enhanced efficacy of traditional 
therapies, while limiting the impact on the normal angiogenic response.
Acidosis
The TME is characterised as possessing a lower pH compared to physiological tissue, a 
result of excess lactic acid from altered tumour cell metabolism. The pH of the TME can 
be as low as 5.5, driven by a phenomenon commonly known as the Warburg effect (Fais 
et  al. 2014). The acidic TME has been shown to drive tumour progression and devel-
opment (Feuerecker et al. 2015). Rofstad et al. (2006) highlighted that tumour cell aci-
dosis significantly increased the formation of pulmonary melanoma metastases in nude 
athymic mice, demonstrating that increased metastasis occurs as a consequence of the 
upregulation of proteolytic enzymes such as MMP-2/9 and the pro-angiogenic protein 
VEGF-A. Proteinase enzymes such as MMP-2/9 have been shown to have optimal activ-
ity at low pH, with activity being upregulated as a consequence of increased phospholi-
pase D, MAPK and NFκB signalling (Kato et al. 2013). Antibody inhibition of VEGF-A 
decreased angiogenic potential by 2.1–3.8-fold, with invasion through  Matrigel® cham-
ber assays being reduced when a known MMP-2/9 inhibitor was used. MMP2/9 inhibi-
tion was also shown to reduce the formation of pulmonary metastases in vivo (Rofstad 
et al. 2006).
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Disruption of the acid/base balance perturbs the uptake of chemotherapeutics, which 
are often acidic or basic in nature, contributing to treatment failure and resistance. For 
example, Swietach et al. (2012) highlighted a twofold decrease in doxorubicin uptake in 
HCT116—colorectal cells—when cultured at pH 6.4 compared to pH 7.4. The authors 
attribute this reduction to pH partitioning, contributing to the ionisation of doxorubicin 
and ion trapping, thereby reducing membrane permeability (Swietach et al. 2012). Pro-
ton pump inhibitors such as omeprazole have been used to reduce tumour cell acidosis, 
but studies have shown little clinical benefit (Marino et al. 2010). Consequently, efforts 
are now focused on exploiting the acidic tumour microenvironment to improve the 
delivery of nanoparticle-encapsulated chemotherapeutics.
Li et  al. (2016) covalently attached a cisplatin pro-drug to a poly(amidoamine) 
(PAMAM) dendrimer block containing tertiary amine groups. Nanoparticles were 
formed via dialysis, removing any unbound polymer, with a mean size of 80 nm at neu-
tral pH. However, under slightly acidic conditions the tertiary amines become proto-
nated allowing for rapid platinum disassociation from the dendrimer block, evidenced 
by a reduction in NP size to 10 nm. The authors hypothesised this pH-sensitive system 
would allow for increased tumour-specific cisplatin uptake, enhancing its efficacy while 
limiting systemic toxicity.
Supporting evidence for this hypothesis was demonstrated with increased platinum 
accumulation in Bx-PC3 (pancreatic cancer) spheroids, with up to a sevenfold increase 
in intratumoural platinum compared to free cisplatin or cisplatin delivered using a non-
pH sensitive system. Furthermore, use of this vehicle translated to significant tumour 
growth delay in a Bx-PC3 xenografts by 82%, compared to 24% for mice treated with 
free cisplatin at a 2 mg/kg dose (Li et al. 2016). Yet, the clinical potential of this delivery 
vehicle for the treatment of pancreatic cancer can be debated. Throughout this study, 
only one pancreatic adenocarcinoma cell line was utilised—Bx-PC3. This cell line cannot 
be considered as a universal model for pancreatic cancer due to the absence of a K-ras 
mutation. Indeed, approximately 90% of the pancreatic patient cohort possess mutations 
in the K-ras oncogene (Cox et al. 2014). Therefore, to assess the translational efficacy of 
the delivery vehicle in pancreatic cancer further studies in ras mutated cell lines such as 
panc-1 and Mia-Paca-2 would be essential. Furthermore, tissue acidosis does not only 
occur in tumour tissue, anaerobic glycolysis creating a build-up of lactic acid can occur 
in numerous parts of the body including muscle tissue. Therefore, if the nanoparticle 
lacks tumour specificity it may accumulate within unwanted tissues leading to unwanted 
side effects.
One approach to circumvent this problem is to conjugate a tumour specific target-
ing ligand to the nanoparticle, an example of which was demonstrated by Cheng et al. 
(2017). The authors developed a pH-responsive folic acid conjugated polydopamine 
modified mesoporous silica nanoparticle for the targeted delivery of doxorubicin. This 
formulation enables tumour specificity due to the presence of the folic acid group. Folic 
acids have high affinity for folate receptors which are overexpressed on the surface of 
cancer cells. Particle size was demonstrated to be 193.08 ± 8.1 nm with a zeta potential 
of − 4.8 ± 0.9 mV. Drug release studies highlighted that 49.5% of the total doxorubicin 
loaded was released at a pH of 2 over a 190 h period, compared to only 28.5% at pH 7.4, 
highlighting the acid sensitivity. In  vivo biodistribution studies demonstrated greatest 
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accumulation of the MSN-Dox-PDA-PEG-FA in the tumour compared to other organs, 
24  h post systemic injection. However, accumulation was still evident within the kid-
ney and liver, particularly at the earlier time points suggesting that folic acid targeting 
may not be specific enough to prevent accumulation in normal organs. Despite this, 
increased doxorubicin efficacy using the mesoporous nanoparticle was observed fol-
lowing systemic administration. At experimental endpoint (16 days) Hela tumour vol-
ume in female athymic mice treated with the MSN-Dox-PDA-PEG-FA nanoparticle 
was reported to be fourfold lower than mice treated with 5 mg/kg of free doxorubicin 
(~ 400 mm3) and tenfold lower than mice treated with saline alone(~ 1000 mm3) (Cheng 
et al. 2017).
This delivery system is a good example of how TME acidosis and active targeting 
can achieve enhanced chemotherapeutic uptake. Hydrodynamic particle size and zeta 
potential are important characteristics that influence the internalisation and therapeu-
tic efficacy of nanoparticle-based therapeutic. A positive surface charge is reported to 
be important for increasing nanoparticle endocytosis. This is because a positive sur-
face charge facilitates target cell contact due to electrostatic interaction towards nega-
tively charged proteoglycans located within the plasma membrane. However, a balance 
must be met as strongly cationic particles have been shown to induce unwanted toxicity 
(Verma and Stellacci 2010). Particles less than 200 nm in diameter are optimally sized 
for uptake via clathrin-mediated endocytosis. Chithrani et al. (2010) reported that AuNP 
size is an important determinant factor for uptake, demonstrating that 50 nm transfer-
rin coated AuNP were more readily internalized than 10 and 100 nm particles due to 
the “wrapping effect” (Zhang et al. 2014). The wrapping effect is the process by which 
the cell membrane encapsulates nanoparticles, independent of receptor/ligand interac-
tions (Bishop et al. 2009). Additionally, developing sub-200 nm functionalised particles 
is important as endocytosis above this size is dominated by caveolae-mediated endo-
cytosis (CME) (Verma and Stellacci 2010). The relevance of this is that many tumour 
sub-types and cell lines including PC-3 (prostate), HT29 (colon carcinoma) and SK-BR3 
(breast) exhibit decreased expression of caveolin-1, an essential protein required for 
the formation of the plasma membrane and caveolin vesicles (Hill et  al. 2008; Bender 
et al. 2000). Therefore, ensuring that particle size remains sub-200 nm should circum-
vent the reduced endocytic potential associated with this tumour-specific alteration. 
Another strategy to improve the physical characteristics of a delivery system and to fur-
ther improve drug uptake is to conjugate the nanoparticle to a cell penetrating peptides, 
discussed further in “Therapeutics targeting the TME”.
Immune component
Tumours are inherently immunogenic exhibiting a significant immune cell infiltrate 
(Fig. 1 and Table 1). In cancers such as glioblastoma, inflammation and an upregulated 
immune response are strongly correlated with enhanced invasion and metastasis (Baek 
et al. 2011). However, successful nanoparticle delivery in the cases of brain tumours face 
the additional barrier of overcoming the blood–brain tumour barrier (BBTB). Recent 
studies have demonstrated that it may be possible to exploit the immune cell profile of 
the TME, piggybacking leukocyte infiltration to enhance NP uptake across the BBTB.
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Pang et  al. (2016) observed that macrophage recruitment is markedly enhanced in 
glioblastoma tumours, with up to a third of the tumour mass composed of macrophage 
cells. The authors hypothesise that using macrophages as a delivery vehicle for doxoru-
bicin-containing nanoparticles (M-DOXNP) will result in increased tumour penetration 
and therapeutic effect compared to doxorubicin delivered in nanoparticle form alone. 
To demonstrate the ability of macrophages to deliver DOXNP, the authors pre-treated 
Raw264.7 murine macrophage cells with DOXNP. Nanoparticles ranging between 
100 and 200  nm were most avidly phagocytosed causing no direct toxicity. Using a 
U87 glioma spheroid model the authors demonstrated increased penetration of the 
M-DOXNP, 56.4 μm from outer rim of spheroid in comparison to the DOXNP which 
only penetrated 36.07 μm. Importantly, in vivo increased circulation times and accumu-
lation within the glioma parenchyma were demonstrated using M-DOXNP compared 
to DOXNP alone, highlighting the potential of exploiting the immune component of the 
TME for NP delivery (Pang et al. 2016). Despite this, several challenges remain with this 
type of delivery system. The authors demonstrated that only 42% of doxorubicin loaded 
into the nanoparticles was released over a 24 h period using the macrophage delivery. 
As such, drug loading would need to be increased to achieve a full therapeutic effect, 
which may directly trigger toxicity within the macrophage cells. Additionally, the clinical 
translation of the approach would prove challenging in that patient cells would require 
pre-harvesting prior to nanoparticle loading and re-administration. Although promis-
ing, this approach remains very much at early stage pre-clinical development.
Extracellular matrix
The extracellular matrix (ECM) is composed of the basement membrane and intersti-
tial matrix, providing tissue structure, regulating cell proliferation and migration (Lu 
et al. 2012). ECM turnover is tightly regulated in healthy tissue. However, ECM dysreg-
ulation is commonly observed in tumours due to aberrant enzyme expression, leading 
to increased stiffness of the ECM, as well as degradation of the basement membrane 
(Gialeli et al. 2011). To date, relatively little is known about the therapeutic potential of 
targeting the ECM in the treatment of cancer. However, as the ECM is not surrounded 
by a plasma membrane nanoparticle therapeutics are an attractive delivery vehicle with 
no extracellular barrier to uptake.
Lysyl oxidase (LOX) is an enzyme responsible for the cross-linking of collagen to elas-
tin in the ECM, inducing ECM rigidity. LOX has been shown to be elevated in numer-
ous tumour subtypes including breast and head and neck cancer (Erler et  al. 2006). 
Overexpression of LOX contributes to the development of a metastatic niche through 
the induction of proliferative signalling pathways such as NF-κB (Mayorca-Guiliani and 
Erler 2013). Kanapathipillai et al. (2012) suggests that inhibition of LOX confers thera-
peutic benefit in the treatment of mammary gland cancer, with the most promising 
approach to date being anti-lox monoclonal antibodies. However, the clinical potential 
of anti-LOX antibodies has largely been impeded by the high concentrations of antibody 
required to induce a therapeutic effect, resulting in a series of unwanted side effects. 
Subsequently,  LOXAb were conjugated to an amphiphilic poly (lactide-co-glycolide-
block-poly (ethylene glycol) (PLGA-b-PEG-COOH) nanoparticle. Conjugation via cova-
lent carbodiimide chemistry produced 220  nm nanoparticles determined by dynamic 
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light scattering (DLS) and TEM. At a nanoparticle/LOXAb concentration of 50 μg/ml, 
a fourfold inhibition of 4T1 cell proliferation and migration was demonstrated. Addi-
tionally, the proliferative rate was unaffected when using an equal concentration of free 
soluble antibody. Importantly, the nanoparticle conjugated antibody resulted in a 25-fold 
reduction in dose to suppress an orthotropic mammary 4TI mouse tumour model com-
pared to free antibody. Conjugation also resulted in an increased therapeutic index, with 
a decrease in adverse effects (Kanapathipillai et al. 2012). However, in vivo biodistribu-
tion studies demonstrated limited tumour specificity, with fivefold higher liver accumu-
lation over tumour following systemic injection. Modifications to this delivery system 
are, therefore, required for increased tumour specificity. Potential modifications may 
include incorporation of a tumour targeting motif or optimisation of the PEG size.
Another key feature of the tumour ECM is evidence of degradation. This degradation 
occurs as a consequence of elevated levels of matrix metalloproteinases such as MMP-2 
and MMP-9. ECM degradation has been shown to enhance the proliferation and metas-
tasis of cancer cells, with MMP expression correlated to advanced, treatment refractory 
phenotypes, in a number of cancers. However, unlike the LOX enzyme there is little evi-
dence of nanoparticle therapies designed to reduce its expression. Instead, a wealth of 
literature is presented as to how its expression can be exploited to enhance nanoparticle 
delivery, stability and drug deposition. Cleavable MMP sequences have been developed 
as a means of removing stealth molecules when a nanoparticle reaches the TME. MMP 
cleavable sequences have been attached to mesoporous silica nanoparticles (MSN) to 
enhance the uptake and therapeutic efficacy of cytotoxic chemotherapeutics. For exam-
ple, Rijt et  al. (2015) conjugated an MMP-9 responsive linker to avidin capped MSNs 
to enhance the uptake and efficacy of cisplatin in a 3D- lung cancer tissue model. The 
authors demonstrated that cisplatin release from the MSN only occurred when recombi-
nant MMP-9 was added, leading to cleavage of the avidin cap.
Tissue extracted from cisplatin-treated k-ras mutated transgenic mice showed 
increased cell death of up to 20-fold, with a corresponding increase in apoptosis (Van 
Rijt et al. 2015). Furthermore, data from the same study showed that when nanoparticles 
are placed on top of the tissue, cisplatin is released and is able to diffuse through the 
sample inducing its therapeutic effect. This may be beneficial as it would remove the 
requirement for additional targeting molecules to ensure nanoparticle internalisation. 
However, this approach may be less effective in large solid tumours with hypoxic cores, 
where transcapillary transport is reduced limiting drug diffusion.
Therapeutics targeting the TME
Gene therapy
Cancer can be described as a disease of genetic mutations, aberrant signalling and 
DNA damage. Consequently, gene therapy has been proposed as an effective treatment 
regime, with 64% of current gene therapy clinical trials designed for the treatment of 
cancer. However, the clinical potential of gene therapy is greatly reduced by the barriers 
faced when delivering oligonucleotide therapeutics. Nucleic acids are vulnerable to rapid 
degradation by the reticuloendothelial system (RES). RES, a component of the innate 
immune system, recognises and clears foreign pathogens and particles through opsoni-
sation and phagocytosis. Additionally, DNA is both hydrophilic and anionic in nature, 
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and therefore, is repelled from the phospholipid bilayer of cell membranes, impeding 
the movement of the DNA into the cytosol (Loughran et al. 2015). Once DNA is inter-
nalised endosomal entrapment can arise with DNA becoming lysed and degraded prior 
to release, rendering its therapeutic potential void (McErlean et al. 2016). Therefore, it is 
essential that gene therapy constructs must be actively targeted to the tumour.
Targeting the TME using nanoparticles as delivery vehicles for nucleic acids has been 
explored as a means of increasing tumour accumulation and efficacy. Nucleic acid nano-
particles have been actively targeted to tumour cells by targeting elevated expression of 
folate and transferrin receptors found on the surface of many tumour cells (Zwicke et al. 
2012; Dixit et al. 2015).
It is well known that the loss of the tumour suppressor p53 is responsible for tumour 
survival and the development of treatment refractory phenotypes in a wide variety of 
cancers (Sigal and Rotter 2000). Consequently, reintroduction of functional p53 could 
prove beneficial for patient survival and treatment outcomes. Senzer et al. (2013) incor-
porated a plasmid encoding for wild-type p53 (wt-p53) in a N-[1-(2,3Dioleoxloxypropyl]-
N–N,Ntrimethylammonium (DOTAP): 1,2Dioleoyl-sn-glycero-3-phosphoethanolamine 
(DOPE) liposomal nanoparticle, conjugated to an anti-transferrin antibody, enabling 
tumour specific targeting. Patients with a variety of solid tumours including colorectal 
and pancreatic received treatment with the nanoparticle conjugates on a dose escalat-
ing regime from 0.6 to 3.6 mg of DNA per infusion. Post treatment, PCR analysis high-
lighted tumour-specific increased expression of p53, with negligible increases observed 
in normal skin biopsies, suggesting that transferrin confers tumour specificity. 7 out of 
11 patients within the study displayed stable disease at a 6-week post-treatment, with an 
increased median survival of 340 days. However, only one patient displayed evidence of 
tumour necrosis, demonstrating the limited effect of SGT-53 as a monotherapy (Senzer 
et  al. 2013). Subsequently, phase one clinical trials have been completed assessing the 
effectiveness of SGT-53 in combination with docetaxel, in patients who previously failed 
to respond to taxane chemotherapy. This study enrolled 14 patients with metastatic 
refractory disease administering 10 infusions of SGT-53 (2.4/3.6 mg) and 3 infusions of 
docetaxel (40, 60 or 70 mg/m2). Preliminary results indicated that 2 patients experienced 
a partial response, with 67% of patients displaying stable disease (Pirollo et  al. 2016). 
Further phase II clinical trials determining the effectiveness of SGT-53 in combination 
with Gemcitabine/Nab-Paclitaxel (NCT02340117) in the treatment of metastatic pan-
creatic cancer are now underway, with results expected in early 2019.
Using targeting ligands, and in particular transferrin specific targeting, has helped 
to overcome intracellular barriers faced when delivering nucleic acid and gene therapy 
(Niidome and Huang 2002). However, premature degradation of targeting molecules can 
occur upon systemic delivery resulting in non-specific protein binding and the forma-
tion of protein corona, triggering phagocytosis and excretion.
Cell‑penetrating peptides
Cell-penetrating peptides (CPP) are short peptide sequences that facilitate cell internali-
sation through a variety of endocytic pathways, without the requirement of specific tar-
geting receptors (Heitz et al. 2009). CPP are known to facilitate the delivery of numerous 
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nanoparticle cargoes in a variety of cell lines and in  vivo models, with peptides being 
easily modified depending on the cargo being delivered (Deshayes et al. 2005).
Early naturally derived CPP such as TAT (sequence: GRKKRRQRRR) and Penetratin 
(sequence: RQIKIYFQNRRMKWKK) are composed of basic amino acids enabling an 
alpha-helical conformation and translocation of cargo across the cell membrane. Exten-
sive research has been carried out into the key components of a CPP structure. Mitch-
ell et al. (2000) highlighted the importance of the number of arginine residues within a 
peptide with respect to penetrating potential. Using fluorescin labelled oligoarginines, 
the authors observed poor endocytosis when incorporating less than 6 arginine residues, 
however, fluorescence increased exponentially when the peptide contained between 7 
and 15 arginine residues. Increasing the arginine composition above 15 residues induced 
significant toxicity and conferred no additional uptake (Mitchell et al. 2000). However, 
the most promising CPP not only contain several arginine residues, but are also amphip-
athic in nature enabling both membrane interaction and pH responsiveness.
One such peptide is RALA. RALA was derived from two alternative cell penetrating 
peptides termed GALA and KALA. GALA (sequence: WEAALAEALAEALAEHLAE-
ALEALAA) is a fusogenic peptide with 7 identical glutamic acid–alanine–leucine–
alanine repeats which provide the peptide with pH-responsive properties, enabling 
embedment within the phospholipid biolayer. However, the use of GALA as a deliv-
ery vehicle is limited by the fact that it cannot condense or bind to negatively charged 
moieties (Li et  al. 2004). To address this, issue the glutamic acid was replaced with 
lysine giving rise to KALA, a positively charged peptide. KALA (sequence: WEAK-
LAKALAKALAKHLAKALAKALKACEA) which displays improved nucleic acid bind-
ing via electrostatic interactions, producing superior transfection efficiencies than 
observed with GALA. However, as KALA does not exhibit pH dependency of its alpha-
helical conformation it was found to induce significant cytotoxicity as a consequence 
of cellular membrane interaction. McCarthy et  al. (2014) developed RALA (sequence: 
WEARLARALARALALRHLARALALRARALRACEA), with the replacement of lysine 
to arginine, greatly improving cell penetration. RALA exhibits reduced toxicity due to 
its alpha-helical structure being pH-responsive, aiding cargo release through endosomal 
membrane interaction (Fig. 2). As such, RALA is a promising delivery platform for gene 
therapy, protecting cargo from unwanted degradation. McCarthy et al. (2014) have also 
shown that RALA produces transfection efficiencies equal to that of the market-leading 
transfection agent lipofectamine, but with the major advantage of less toxicity (Mccarthy 
et al. 2014; Bennett et al. 2015).
RALA has been shown to have the potential for the delivery of bisphosphonate drugs 
(BP’S), such as alendronate, which have bone-targeting specificity. This opens up the 
options of treating metastatic disease which form bone lesions. However, the clinical 
application of BP’s is impeded by systemic toxicity. Massey et al. (2016) present evidence 
that encapsulating BP’s into nanoparticle structures using RALA allows for improved 
delivery and the potentiation of anti-cancer effects. Using an MTS cell viability assay 
the authors highlight that BP’s which previously show no anticancer properties in the 
PC-3 cell line, induce significant cytotoxicity when delivered using RALA. Importantly, 
blank RALA nanoparticles induced no direct toxicity. RALA-alendronate particles, 
when directly injected into the tumour were demonstrated to delay tumour growth and 
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increased survival by 56.3% in PC-3 xenografts (Massey et al. 2016). These studies high-
light RALA, along with other CPP as an exciting delivery vehicle for a wide range of 
negatively charged moieties,
However, the biodistribution profile of RALA nanoparticles have highlighted high 
levels of accumulation in normal organs such as the lungs and liver, rather than the 
intended tumour (Mccarthy et al. 2014). This could potentially lead to the occurrence 
of off-target side effects. A similar distribution profile has been shown using alternative 
arginine-rich peptide delivery systems such as TAT and penetratin, suggesting that it 
is the high positive charge of the particles that lead to off-target accumulation (Nakase 
et al. 2012). However, particles possessing a neutral or negative surface charge display 
reduced cell-penetrating ability, therefore, a careful balance must be achieved. A poten-
tial strategy to reduce surface charge but still maintain a cationic property is through the 
inclusion of stealth molecules.
Metallic nanoparticles
Metallic nanoparticles such as gold nanoparticles (AuNP) can take advantage of the 
leaky tumour vasculature, accumulating in tissue due to the EPR effect. This has led to 
a variety of possible applications including radiosensitisers, contrast agents and drug 
delivery vehicles (Coulter et al. 2013; McQuaid et al. 2016).
AuNPs have been used as delivery vehicles for cytotoxic chemotherapeutics such as 
5-Fluorouracil, docetaxel and platinum-based chemotherapeutics such as oxaliplatin, all 
of which are hindered by low tumour-specific localisation, inefficient target cell inter-
nalisation and normal tissue toxicity. AuNPs are chemically inert and do not interfere 
Fig. 2 Cell penetrating peptide RALA enhances the delivery of therapeutic cargo. a RALA is complexed with 
negatively charged cargo, with particles forming through the formation of electrostatic interactions. b simple 
schematic of a cell. c Upon endocytosis nanoparticles can become trapped within the endosome. d RALA 
adopts an alpha-helical confirmation in the low pH of the endosome, allowing for interaction, disruption of 
the endosomal membrane and the release and trafficking of cargo to target tissues/organelles
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with the structure or mechanism of a drug, but can enhance chemotherapy uptake and 
efficacy. Brown et  al. (2010) conjugated the active region of oxaliplatin (Pt[R,R-dach]) 
to a PEGylated 31 nm AuNP. This resulted in particles of 176 nm ± 25 nm in diameter 
with a zeta potential of 14 mV ± 7.0 mV. In vitro, inductively coupled plasma mass spec-
trometry (ICP-MS) studies indicated that AuNP-oxaliplatin resulted in > twofold uptake 
enhancement in A549 lung carcinoma cells, compared to free oxaliplatin. The increased 
tumour cell internalisation of oxaliplatin, corresponded to an increase in efficacy with 
the  LD50 concentration reduced by ~ 40% from 0.774 μM to 0.495  nM. (Brown et  al. 
2010).
Evidence within the literature also suggests that AuNP may have antiangiogenic activ-
ity and as such could be used to target specific proteins and receptors that are up-reg-
ulated within the TME. Mukherjee et al. (2005) hypothesised that due to the previous 
therapeutic use of gold in rheumatoid arthritis, that AuNP may prove useful inhibitors of 
angiogenesis. Using 5 nm AuNP the authors inhibited VEGF and basic fibroblast growth 
factor (bFGF) induced proliferation of both HUVEC and NIH3T3 cells, without trigger-
ing toxicity. At a dose of 670 nmol/l, the nanoparticles significantly decreased angiogen-
esis and oedema in a nude mouse ear experiment. Mechanistic studies demonstrated 
that this anti-angiogenic effect arose as a consequence of non-specific AuNP binding 
to the heparin domain of VEGF165 and BFGF, triggering a reduction in Rho signalling 
activity (Mukherjee et al. 2005). HUVEC (endothelial) and NIH3T3 (fibroblast) cells are 
abundant within the TME and play a crucial role in the signalling and growth response 
of tumours. Previous studies have shown AuNP to have minimal anti-proliferative activ-
ity and low toxicity, affirming their primary use as treatment sensitizers and drug carri-
ers (Botchway et al. 2015).
Despite significant evidence presenting the potential clinical application of AuNP, a 
number of factors remain, impeding clinical translation. Metallic nanoparticles and par-
ticularly AuNP can be subject to rapid clearance through the reticuloendothelial system 
(RES) (Haley and Frenkel 2008). This is particularly true of unfunctionalised citrate-
capped AuNP that are stable in neutral solutions such as phosphate buffered saline (PBS) 
due to electrostatic repulsion. However, when placed in full serum conditions (culture 
medium) or when systemically injected, non-specific protein absorption results in parti-
cle agglomeration, opsonisation and phagocytic clearance. In some cases, nanoparticles 
can accumulate in the liver and spleen, after which particle toxicity becomes a prob-
lem. The addition of stealth molecules on the surface of the particles has been shown to 
improve stability and consequently circulation and retention times.
The PEG dilemma
Stealth polymers such as Poly-ethylene glycol (PEG) are hydrophilic in nature, coating 
hydrophobic nanoparticles and increasing particle stability through altered polarity (Liu 
et  al. 2007). PEGylation prevents premature opsonisation and monocyte recognition 
thereby increasing circulation and retention time (Kumar et al. 2013). This is of particu-
lar importance in an in vivo context, enabling more predictable modelling of the biologi-
cal response. However, studies have demonstrated that repeated administration of PEG 
can lead to a sensitised immune response and enhanced clearance rates. Yet, perhaps the 
biggest problem associated with the inclusion of stealth molecules is the negative impact 
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on particle endocytosis, with increased polymer chain length conferring increased sta-
bility, but decreased uptake. Cruje and Chithrani (2015) assessed the uptake of 3 differ-
ent AuNP preparations—(unPEGylated, 2  kDa PEG 50% coverage or 5  kDa PEG 50% 
coverage), in MCF-7 cells. Importantly, the incorporation of PEG attenuated particle 
uptake by up to tenfold in cells exposed to the 5 kDa version (Schellekens et al. 2013). 
This effect formed what is informally described as the “PEG dilemma”. It is, therefore, 
essential to refine the use of stabilising polymers to establish the maximum molecular 
weight/nanoparticle coverage that will enhance stability without impeding uptake.
Current efforts are focused on determining whether PEG molecules can be cleaved 
in a site-specific manner, enabling stability upon administration whilst also ensuring 
efficient endocytosis. One such approach involves PEG cleavage within the TME by 
exploiting tumour elevated levels of matrix metalloproteinase enzymes. Matrix metal-
loproteinases (MMPs) describe a class of extracellularly-expressed, zinc-dependent 
proteases that have a key role in physiological processes requiring ECM modification 
(Vartak and Gemeinhart 2007). In cancer, MMPs are responsible for the degradation 
of the basement membrane enabling release of growth factors such as VEGF, which 
promote proliferation and metastasis (Cathcart et  al. 2015). Hatakeyama et  al. 2007 
exploited elevated levels of MMP-2 to promote cleavage of a 5K PEG on the MEND 
delivery system for nucleic acids (PPD-PEG-5K). Following an i.v injection in male nude 
BALB/c mice with a HT1080-Luc xenograft, a 70% reduction in luciferase activity was 
observed (Hatakeyama et al. 2007). Li et al. (2013) also developed an MMP responsive 
delivery system for gene therapy in the treatment of metastatic breast cancer (Li et al. 
2013). The PAT-SPN nanoparticle was PEGylated to improve bioavailability, however, 
the PEG coating was cleaved once the nanoparticle reached a location rich in MMP-7. 
The authors demonstrated a 2.5-fold increase in target cell internalisation and therapeu-
tic effect with the cleavable PEG nanoparticles compared to non-cleavable PEG nano-
particles and free siRNA alone. They attributed the increased cell uptake to exposure of 
the cationic corona which occurs upon PEG cleavage, enabling the siRNA to be inter-
nalised. Both studies suggest that exploiting environmental signals within the TME may 
prove beneficial for enhancing drug delivery with several other studies also suggesting 
this approach may prove beneficial for the delivery of metallic nanoparticles. However, 
the development and validation of a MMP responsive nanoparticle systems is challeng-
ing using in vitro systems. This is due to the fact that cells which exist in a homogeneous 
monolayer express low levels of enzymes such as MMPs compared to in vivo models. 
Consequently, it may be necessary to artificially induce expression, which in turn makes 
validation of enzyme responsive nanoparticle systems increasingly difficult.
An alternative approach to the cleavage of PEG within the TME is to exploit the acidic 
nature of the TME as previously discussed “TME and vasculature” section. Zhao et al. 
(2017) synthesised a “smart” cleavable pH sensitive PEG-s-PEI linker which was used 
to produce self-assembled nanoparticles encapsulating the chemotherapeutic doc-
etaxel (DTX) and the non-steroidal anti-inflammatory drug indomethacin (IND). IND 
was used to limit weight loss often observed with cytotoxic therapies in both pre-clin-
ical in vivo studies and in the clinic. The authors demonstrated PEG cleavage in acidic 
conditions (pH 7.4–6.5) through a decreased surface potential. PEG cleavage resulted 
in an increased release of DTX/IND over a 12 h period at pH 6.5 (max—0.4 nM/mg) 
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compared to 0.2  nM/mg at pH 7.4 in the B16F10 tumour model. Furthermore, DTX/
IND PEG-s-PEI nanoparticles delivered significant reductions in B16F10 and HepG2 
tumour cell viability over free docetaxel at pH 6.5, confirming that cell acidosis contrib-
utes to treatment resistance and failure. Importantly, significant changes in tumour vol-
ume were demonstrated using a B16F10 xenograft when treated intravenously with the 
cleavable DOX/IND nanoparticle, compared to both free DTX and the non-cleavable 
DTX/IND-PEG-b-PEI nanoparticle. This decrease corresponded to the increased ability 
of the particle to exploit the TME, causing PEG cleavage that allowed increased doc-
etaxel tumour specific accumulation (Zhao et al. 2017).
Conclusions
As discussed throughout, exploiting characteristics of the TME for nanoparticle design 
and therapy has shown significant potential for enhancing drug delivery and improving 
cancer therapeutics. Tumours can no longer be considered in isolation as a mass of rap-
idly proliferating neoplastic cells. Instead, tumours are a dynamic network of immune 
and endothelial cells connected by a chaotic and aberrant vasculature system. High IFP, 
hypoxia and low pH have now all be shown as indicative of the TME. It is known that 
these characteristics impede the delivery and efficacy of numerous chemotherapeutics. 
However, evidence presented within this review suggest that nanoparticle therapies can 
exploit these aberrant characteristics, actively or passively accumulating within tumour 
tissue. Consequently, nanoparticle therapies are widely considered to represent the next-
generation of cancer therapeutics.
Currently, translation of nanoparticle therapies to clinic remains limited due to poor 
stability, circulation time and internalisation. Conjugation of stealth molecules often 
improves stability, however, as discussed stealth molecules can themselves impede target 
cell uptake. This review outlines a number of possible modifications that could circum-
vent these difficulties, including the use of cell-penetrating peptides and the develop-
ment of TME responsive nanoparticles. To date, these approaches remain in their 
infancy with in vitro validation remaining challenging. Yet, as our knowledge and under-
standing of these relatively new technologies continue to emerge, it is likely that thera-
peutic strategies which exploit features of the tumour microenvironment will eventually 
hold prominence routine in clinical practice.
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